$94.60
0.17% yesterday
Nasdaq, Oct 21, 10:04 pm CET
ISIN
NL0011606264
Symbol
MRUS

Merus N.V. Stock price

$94.60
+25.41 36.73% 1M
+51.37 118.83% 6M
+52.55 124.97% YTD
+43.00 83.33% 1Y
+71.96 317.84% 3Y
+81.70 633.33% 5Y
+84.56 842.23% 10Y
+84.56 842.23% 20Y
Nasdaq, Closing price Tue, Oct 21 2025
+0.16 0.17%
ISIN
NL0011606264
Symbol
MRUS
Industry

Key metrics

Basic
Market capitalization
$7.2b
Enterprise Value
$6.5b
Net debt
positive
Cash
$710.2m
Shares outstanding
75.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
127.5 | 134.7
EV/Sales
114.9 | 121.4
EV/FCF
negative
P/B
8.5
Financial Health
Equity Ratio
82.8%
Return on Equity
-33.2%
ROCE
-39.1%
ROIC
-159.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$56.2m | $53.2m
EBITDA
$-344.5m | $-386.8m
EBIT
$-347.0m | $-404.1m
Net Income
$-385.5m | $-460.9m
Free Cash Flow
$-313.3m
Growth (TTM | estimate)
Revenue
59.8% | 47.3%
EBITDA
-77.1% | -43.5%
EBIT
-76.0% | -48.5%
Net Income
-129.9% | -114.1%
Free Cash Flow
-200.8%
Margin (TTM | estimate)
Gross
-
EBITDA
-612.7% | -726.9%
EBIT
-617.1%
Net
-685.6% | -866.3%
Free Cash Flow
-557.2%
More
EPS
$-5.4
FCF per Share
$-4.1
Short interest
3.8%
Employees
291
Rev per Employee
$120.0k
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,002 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Merus N.V. forecast:

10x Buy
43%
13x Hold
57%

Analyst Opinions

23 Analysts have issued a Merus N.V. forecast:

Buy
43%
Hold
57%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
56 56
60% 60%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 92 92
36% 36%
163%
- Research and Development Expense 312 312
89% 89%
554%
-345 -345
77% 77%
-613%
- Depreciation and Amortization 2.44 2.44
4% 4%
4%
EBIT (Operating Income) EBIT -347 -347
76% 76%
-617%
Net Profit -386 -386
130% 130%
-686%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
GlobeNewsWire
about 20 hours ago
Media Release COPENHAGEN, Denmark; October 21, 2025 Genmab A/S (Nasdaq: G MAB ) (“Genmab”) announced today that it is commencing, through a wholly owned subsidiary, Genmab Holding II B.V. (“ Purchaser ”), a cash tender offer (the “Offer”) to purchase all of the issued and outstanding common shares (“Common Shares”) of Merus N.V.
Neutral
GlobeNewsWire
8 days ago
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile
Neutral
GlobeNewsWire
9 days ago
-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m.
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 291
Founded 2003
Website merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today